Search results
Results From The WOW.Com Content Network
Guardant Health said the test would be the "first and only comprehensive biopsy-free cancer test available". [7] In 2016, the company announced clinical trial results demonstrating the test "detected disease-associated genetic mutations that were also present in 94% to 100% of the solid tissues extracted from the study's subjects".
Guardant Health said its blood test to detect cancer that starts in the colon or rectum got an approval from the U.S. Food and Drug Administration, with the test moving closer toward gaining ...
Guardant Reveal, which runs on Guardant’s Smart Liquid Biopsy platform, is a blood test that uses epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA), a marker of minimal ...
Guardant's application for Shield was based on a study that showed the test detected 83% of colorectal cancers, while Exact's Cologuard had 92.3% sensitivity rate, according to the FDA's documents.
In 2017, a venture capital funding round led by SoftBank raised $360 million, [26] allowing Guardant Health to expand operations globally [35] and continue to focus on accelerating progress towards early cancer detection. [31] [36] Eltoukhy and Talasaz rang the opening bell at the Nasdaq when Guardant Health went public (IPO) on October 4, 2018 ...
Guardant Health is seeking approval for Shield, a blood-based colorectal cancer (CRC) screening test for average-risk adults. ... If approved, Guardant's Shield test could become the second blood ...
Guardant's application for Shield was based on a study, which showed that the test detected 83% of colorectal cancers and 13% of advanced adenomas, the pre-cancerous tumors.
The Emotional Intelligence Appraisal is a skill-based self-report and measure of emotional intelligence (EQ) developed to assess emotionally competent behavior that provides an estimate of one's emotional intelligence.